Almirall, S.A.

portfolio across cardiovascular, respiratory, CNS, gastrointestinal, urology, osteomuscular and diabetes areas in Spain. It runs its own R&D (a centre in Sant Feliu de Llobregat and the Reinbek Centre of Excellence for Dermatology in Germany) and manufactures at pharmaceutical and chemical plants in Sant Andreu de la Barca and Sant Celoni (Spain) and Reinbek (Germany, formerly Hermal). Its innovative dermatology line includes the biologics Ebglyss (lebrikizumab) and Ilumetri (tildrakizumab), Skilarence (dimethyl fumarate), Wynzora, Actikerall, Ony-Tec and Klisyri/Tirbanibulina.